Inspiratory Flow Rate Capability in Pulmonary Fibrosis Patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

In this observational study, researchers measure peak inspiratory flow rate (PIFR) and inspiratory time (EIT) in patients with pulmonary fibrosis using a device that simulates dry powder inhaler resistance. Participants perform breathing tests at medium and high resistance settings, with rests between tests, to understand how resistance affects inhalation performance. The study uses the In-Check DIAL G16 to mimic various inhaler resistances and aims to enroll 60 adults with IPF or PPF. Results may inform inhaler device selection and prescription practices for this population.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Age 18-80 years (inclusive), either sex.
2. Diagnosis of pulmonary fibrosis (IPF or PPF) according to the ATS/ERS/JRS/ALAT 2022 guidelines (with traceable diagnostic evidence such as medical records, confirmed by a radiologist).
3. Forced vital capacity (FVC) ≥ 45% of predicted normal value within 2 months before screening.
4. Diffusing capacity for carbon monoxide (DLCO) \> 25% of predicted normal value within 2 months before screening.
5. Voluntary participation with written informed consent.

Exclusion Criteria:

1. Patients with impaired consciousness, dementia, or various psychiatric disorders.
2. Patients unable to operate the inspiratory flow measurement device as instructed by the investigator.
3. Patients with major diseases or conditions other than the IPF under study that, in the investigator's judgment, may put the patient at risk by participating in the trial.
4. Any participant deemed unsuitable for enrollment by the investigator.

Where it's running

• Shanghai Pulmonary Hospital
  Shanghai, Shanghai Municipality, China Recruiting

Study contacts

• Study coordinator: Jiuwu Bai
• Email: yv59@163.com
• Phone: +86 13651602925

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Registry for individuals affected by pulmonary fibrosis

  This study invites people with pulmonary fibrosis, along with their caregivers and family members, to share their experiences through online surveys to help researchers understand the condition better and possibly reach out for future studies.

  Recruiting Pulmonary Fibrosis Foundation · Chicago, Illinois · NCT05382572

• Nerandomilast in IPF and Progressive Fibrosis: Real-World Data

  This study tests whether nerandomilast helps slow lung function decline in adults with IPF or progressive fibrotic lung disease in routine clinical care.

  Recruiting at 4 sites Tel Aviv Medical Center · Ashkelon and 3 other locations · NCT07919015

• New IPF drug ORJ-001 tested in adults with IPF

  A phase 2 study tests ORJ-001 versus placebo in adults with idiopathic pulmonary fibrosis to see if it is tolerated and whether it helps lung function.

  Recruiting at 2 sites Phase 2 Oorja Bio, Inc. · Doral, Florida and 1 other locations · NCT07869147

• Nalbuphine ER for IPF-related chronic cough

  This study tests whether extended-release nalbuphine tablets can reduce chronic cough in people with idiopathic pulmonary fibrosis.

  Recruiting at 4 sites Phase 3 Trevi Therapeutics · Wilmington, Delaware and 3 other locations · NCT07868419

• Treprostinil Palmitil Inhalation Powder for Progressive Pulmonary Fibrosis

  A 52-week study will test whether once-daily Treprostinil Palmitil Inhalation Powder helps lung function in adults with progressive pulmonary fibrosis compared to placebo.

  Recruiting Phase 3 Insmed Incorporated · DuBois, Pennsylvania · NCT07805785

• Photon-counting CT vs standard HRCT to help diagnose IPF and other ILDs

  This study tests whether photon-counting CT can improve identifying IPF and other ILDs compared with standard HRCT for patients discussed in multidisciplinary teams.

  Recruiting Istituto Clinico Humanitas · Rozzano, Italy · NCT07790614

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.